PH12017501184B1 - Pharmaceutical composition for treating diabetes - Google Patents
Pharmaceutical composition for treating diabetesInfo
- Publication number
- PH12017501184B1 PH12017501184B1 PH12017501184A PH12017501184A PH12017501184B1 PH 12017501184 B1 PH12017501184 B1 PH 12017501184B1 PH 12017501184 A PH12017501184 A PH 12017501184A PH 12017501184 A PH12017501184 A PH 12017501184A PH 12017501184 B1 PH12017501184 B1 PH 12017501184B1
- Authority
- PH
- Philippines
- Prior art keywords
- pharmaceutical composition
- treating diabetes
- dpp
- inhibitor
- metformin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Abstract
The present invention relates to a pharmaceutical composition for treating diabetes, containing metformin and a DPP-TV inhibitor. The pharmaceutical composition for treating diabetes according to the present invention can cut off the contact between the DPP-TV inhibitor and metformin, so that the lifespan of the composition is increased and the amount as well as the kind of impurities contained in the composition is reduced. Furthermore, the DPP-TV inhibitor can be rapidly released and the sustained-release of metformin can be controlled.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140186677A KR101526825B1 (en) | 2014-12-23 | 2014-12-23 | Pharmaceutical Compositions for The Treatment of Diabetes |
PCT/KR2015/014096 WO2016105084A2 (en) | 2014-12-23 | 2015-12-22 | Pharmaceutical composition for treating diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
PH12017501184B1 true PH12017501184B1 (en) | 2017-12-18 |
PH12017501184A1 PH12017501184A1 (en) | 2017-12-18 |
Family
ID=53500898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12017501184A PH12017501184A1 (en) | 2014-12-23 | 2017-06-22 | Pharmaceutical composition for treating diabetes |
Country Status (7)
Country | Link |
---|---|
KR (1) | KR101526825B1 (en) |
CN (1) | CN107205969B (en) |
MY (1) | MY196438A (en) |
PH (1) | PH12017501184A1 (en) |
SG (1) | SG11201705194XA (en) |
TW (1) | TW201628602A (en) |
WO (1) | WO2016105084A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106421794A (en) * | 2016-09-27 | 2017-02-22 | 黑龙江珍宝岛药业股份有限公司 | Drug compound for treating type II diabetes and preparation method thereof |
MX2020002312A (en) * | 2017-09-29 | 2020-09-17 | Hanmi Pharm Ind Co Ltd | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin. |
KR102500835B1 (en) * | 2017-10-24 | 2023-02-17 | 한미약품 주식회사 | Complex Preparations Comprising Lingliptin and Metformin as an active ingredients and preparing method thereof |
TR201721824A2 (en) * | 2017-12-26 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN |
CN113116842A (en) * | 2019-12-31 | 2021-07-16 | 广州玻思韬控释药业有限公司 | Stomach retention tablet |
TW202329921A (en) * | 2021-10-08 | 2023-08-01 | 南韓商賽特瑞恩股份有限公司 | Pharmaceutical composition for treatment of diabetes with improved stability |
CN115715768A (en) * | 2022-11-24 | 2023-02-28 | 浙江昂利泰制药有限公司 | Small sitagliptin-metformin sustained release tablet and preparation method thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080630A1 (en) * | 2004-09-23 | 2006-08-03 | Handok Pharmaceuticals Co., Ltd. | Pharmaceutical combination preparation for oral delivery for the treatment of diabetes mellitus |
KR100760430B1 (en) * | 2004-12-31 | 2007-10-04 | 한미약품 주식회사 | Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof |
KR101438234B1 (en) * | 2005-06-03 | 2014-09-04 | 미쓰비시 타나베 파마 코퍼레이션 | Concomitant pharmaceutical agents and use thereof |
CN101365432B (en) * | 2005-12-16 | 2011-06-22 | 默沙东公司 | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
CN101168059A (en) * | 2007-10-12 | 2008-04-30 | 重庆医药工业研究院有限责任公司 | Stable medicinal composition containing biguanide, sulfonylurea and thiazolidinedione and preparation method thereof |
CN101168060B (en) * | 2007-10-12 | 2012-06-13 | 重庆医药工业研究院有限责任公司 | Stable medicinal composition containing biguanide and sulfonylurea and preparation method thereof |
JP2011510986A (en) * | 2008-02-05 | 2011-04-07 | メルク・シャープ・エンド・ドーム・コーポレイション | Combination pharmaceutical composition of metformin and dipeptidyl peptidase-IV inhibitor |
CA2752437C (en) * | 2009-02-13 | 2017-07-11 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
PL2590634T3 (en) * | 2010-07-09 | 2016-10-31 | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin | |
UY33937A (en) * | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS |
US9555001B2 (en) * | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
KR101409330B1 (en) * | 2012-05-11 | 2014-06-18 | 안국약품 주식회사 | Sustained-Release combination preparations for the treatment of diabetes mellitus having enhanced compliance and preparation method thereof |
KR20140013436A (en) * | 2012-07-24 | 2014-02-05 | 한미약품 주식회사 | Composite formulation for oral administration comprising metformin and rosuvastatin |
CN103285398B (en) * | 2013-06-28 | 2015-07-22 | 青岛黄海制药有限责任公司 | Compound preparation containing DPP-IV (dipeptidyl peptidase-IV) inhibitor and type-II diabetes medicine and preparation method thereof |
-
2014
- 2014-12-23 KR KR1020140186677A patent/KR101526825B1/en active IP Right Grant
-
2015
- 2015-12-22 SG SG11201705194XA patent/SG11201705194XA/en unknown
- 2015-12-22 MY MYPI2017702340A patent/MY196438A/en unknown
- 2015-12-22 WO PCT/KR2015/014096 patent/WO2016105084A2/en active Application Filing
- 2015-12-22 TW TW104143123A patent/TW201628602A/en unknown
- 2015-12-22 CN CN201580070627.7A patent/CN107205969B/en active Active
-
2017
- 2017-06-22 PH PH12017501184A patent/PH12017501184A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201705194XA (en) | 2017-07-28 |
MY196438A (en) | 2023-04-11 |
PH12017501184A1 (en) | 2017-12-18 |
TW201628602A (en) | 2016-08-16 |
CN107205969A (en) | 2017-09-26 |
KR101526825B1 (en) | 2015-06-08 |
WO2016105084A3 (en) | 2016-09-09 |
WO2016105084A2 (en) | 2016-06-30 |
CN107205969B (en) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501184B1 (en) | Pharmaceutical composition for treating diabetes | |
PH12017502297A1 (en) | Antibacterial compounds | |
MX2018008052A (en) | Lsd1 inhibitors. | |
MX2018012016A (en) | Bicyclic compounds. | |
AU2015208932A8 (en) | (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors | |
PH12015502075B1 (en) | Treatment of cataplexy | |
EA033325B1 (en) | Bromodomain inhibitors | |
CR20160582A (en) | COMPOSITION TO TREAT DIABETES, CONTAINING A PROLONGED ACTION INSULIN ANALOG AND A PROLONGED ACTION INSULINOTROPIC PEPTIDE CONJUGATE | |
MX2018002962A (en) | Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production. | |
MX2017002538A (en) | Sorbens for binding metals and production thereof. | |
IN2015DN00438A (en) | ||
MX2017001352A (en) | Pyrrolidinone derivatives as metap-2 inhibitors. | |
MX2017007188A (en) | Antimycotic compound. | |
TN2016000535A1 (en) | Ppar compounds for use in the treatment of fibrotic diseases. | |
MX2017006712A (en) | Matrix metalloproteinase production inhibitor. | |
MX2016012758A (en) | Hyperosmolar composition of hyaluronic acid. | |
PH12017500613A1 (en) | Improved peptide inhibitors of sodium channels | |
PH12017501897A1 (en) | 2-thiopyrimidinones | |
EA201691465A1 (en) | MEANS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
MX2017003020A (en) | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation. | |
MX369174B (en) | Process for preparing a compound. | |
MX2017006548A (en) | 2-octylcyclopropyl-1-carboxylic acid and the isomers thereof, and uses of same. | |
BR112015031978A2 (en) | pan and pan background | |
BR112015020973A2 (en) | pan and pan background | |
UA114811C2 (en) | New compositions for treating amyotrophic lateral sclerosis |